[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100330429":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":46,"centralContacts":50,"locations":55,"responsibleParty":73,"collaborators":45,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":45,"eligibilityCriteria":81,"healthyVolunteers":77,"sex":82,"minAge":83,"maxAge":45,"enrollmentInfo":84,"targetDuration":45,"studyType":87,"phases":88,"briefSummary":91,"conditions":92,"keywords":45,"overallStatus":58,"whyStopped":45,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"Stanford University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Diagnostic (panitumumab-IRDye800, surgery, NIR)","EXPERIMENTAL","Participants receive panitumumab- IRDye800 IV over 60 minutes on day 0, and then undergo NIR and surgery within 1-5 days.",[13,14,15,16],"Procedure: Near-Infrared Fluorescence Imaging","Drug: Panitumumab-IRDye800","Other: Pharmacokinetic Study","Procedure: Therapeutic Conventional Surgery",[18,26,34,41],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"PROCEDURE","Near-Infrared Fluorescence Imaging","Undergo imaging",[9],[24,25],"NIR Fluorescence Imaging","NIR Optical Imaging",{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Panitumumab-IRDye800","Given IV",[9],[32,33],"Panitumumab IRDye 800","RDye800-Panitumumab Conjugate",{"type":6,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"Pharmacokinetic Study","Correlative studies",[9],[39,40],"PHARMACOKINETIC","PK Study",{"type":19,"name":42,"description":43,"armGroupLabels":44,"otherNames":45},"Therapeutic Conventional Surgery","Undergo surgery",[9],null,[47],{"name":48,"affiliation":5,"role":49},"Natalie Lui","PRINCIPAL_INVESTIGATOR",[51],{"name":48,"role":52,"phone":53,"phoneExt":45,"email":54},"CONTACT","650-721-2086","natalielui@stanford.edu",[56],{"facility":57,"status":58,"city":59,"state":60,"zip":61,"country":62,"countryCode":63,"cosmosGeoPoint":64,"geoPoint":69,"contacts":70},"Stanford University, School of Medicine","RECRUITING","Palo Alto","California","94304","United States","US",{"type":65,"coordinates":66},"Point",[67,68],-122.14302,37.44188,{"lat":68,"lon":67},[71,72],{"name":48,"role":52,"phone":53,"phoneExt":45,"email":54},{"name":48,"role":49,"phone":45,"phoneExt":45,"email":45},{"type":74,"investigatorFullName":45,"investigatorTitle":45,"investigatorAffiliation":45,"oldNameTitle":45,"oldOrganization":45},"SPONSOR","100330429","phase-1-panitumumab-irdye800-in-detecting-cancer-in-participants-with-lung-cancer-during-surgery-100330429",false,"NCT03582124","Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery","A Phase I\u002FII Study Evaluating the Safety and Pharmacokinetics of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Lung Cancer During Surgical Procedures","Inclusion Criteria:\n\n* Patients with lung nodule or mass concerning for malignancy, either primary lung cancer or lung metastases, whether or not it is biopsy-proven\n* Patients scheduled to undergo planned standard of care surgical resection for a lung nodule or mass with diagnostic and\u002For curative intent for lung cancer\n* Karnofsky performance status of at least 70% or Eastern Cooperative Oncology Group (ECOG)\u002FZubrod level 0-2\n* Hemoglobin ≥ 9 gm\u002FdL\n* White blood cell count \\> 3000\u002Fmm\\^3\n* Platelet count ≥ 100,000\u002Fmm\\^3\n* Serum creatinine ≤ 1.5 times upper reference range\n\nExclusion Criteria:\n\n* Received an investigational drug within 30 days prior to first dose of panitumumab-IRDye800\n* Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment\n* History of infusion reactions to monoclonal antibody therapies\n* Pregnant or breastfeeding\n* Magnesium or potassium lower than the normal institutional values\n* Subjects receiving class IA (quinidine, procanamide) or class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents\n* Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis\n* Prisoners, institutionalized individuals, and patients unable to consent for themselves","ALL","19 Years",{"count":85,"type":86},30,"ESTIMATED","INTERVENTIONAL",[89,90],"PHASE1","PHASE2","This phase I\u002FII trial studies the best dose and timing of panitumumab-IRDye800 in detecting cancer in participants with lung cancer during the surgery. Panitumumab-IRDye800 is a combination of the antibody drug panitumumab and IRDye800CW, an investigational dye that can be seen using a special camera. Panitumumab-IRDye800 may attach to tumor cells and make them more visible during surgery in patients with lung cancer.",[93,94,95,96,97],"Lung Carcinoma","Metastatic Malignant Neoplasm in the Lung","Stage IV Lung Cancer AJCC v8","Stage IVA Lung Cancer AJCC v8","Stage IVB Lung Cancer AJCC v8","2026-02-07",{"date":100,"type":101},"2026-02-10","ACTUAL",{"date":103,"type":101},"2018-07-19",{"date":105,"type":86},"2026-09",{"name":5,"class":6},1]